662 related articles for article (PubMed ID: 34524918)
1. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.
Taramasso L; De Vito A; Ricci ED; Orofino G; Squillace N; Menzaghi B; Molteni C; Gulminetti R; De Socio GV; Pellicanò GF; Sarchi E; Celesia BM; Calza L; Rusconi S; Valsecchi L; Martinelli CV; Cascio A; Maggi P; Vichi F; Angioni G; Guadagnino G; Cenderello G; Dentone C; Bandera A; Falasca K; Bonfanti P; Di Biagio A; Madeddu G;
AIDS Patient Care STDS; 2021 Sep; 35(9):342-353. PubMed ID: 34524918
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;
J Int AIDS Soc; 2019 Jan; 22(1):e25227. PubMed ID: 30663278
[TBL] [Abstract][Full Text] [Related]
3. Switch to dolutegravir is well tolerated in Thais with HIV infection.
Goh OQ; Colby DJ; Pinyakorn S; Sacdalan C; Kroon E; Chan P; Chomchey N; Kanaprach R; Prueksakaew P; Suttichom D; Trichavaroj R; Spudich S; Robb ML; Phanuphak P; Phanuphak N; Ananworanich J;
J Int AIDS Soc; 2019 Jul; 22(7):e25324. PubMed ID: 31294931
[TBL] [Abstract][Full Text] [Related]
4. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
Fusco P; Nasta P; Quiros-Roldan E; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112904
[No Abstract] [Full Text] [Related]
6. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
7. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
9. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort.
Ciccullo A; Baldin G; Borghi V; Lagi F; Latini A; d'Ettorre G; Oreni L; Fusco P; Capetti A; Fabbiani M; Giacomelli A; Grimaldi A; Madeddu G; Sterrantino G; Mussini C; Di Giambenedetto S
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062367
[TBL] [Abstract][Full Text] [Related]
10. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
12. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Cervo A; Valenti D; Callegaro A; Mussini C
BMC Infect Dis; 2022 Oct; 22(1):782. PubMed ID: 36224538
[TBL] [Abstract][Full Text] [Related]
14. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
[TBL] [Abstract][Full Text] [Related]
15. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
Cid-Silva P; Llibre JM; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Pernas-Souto B; Martín-Herranz I; Castro-Iglesias Á; Poveda E
Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):442-446. PubMed ID: 28627771
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
[TBL] [Abstract][Full Text] [Related]
18. Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study.
Lagi F; Botta A; Ciccullo A; Picarelli C; Fabbiani M; di Giambenedetto S; Borghi V; Mussini C; Bartoloni A; Sterrantino G
HIV Res Clin Pract; 2021 Aug; 22(4):96-101. PubMed ID: 34437817
[No Abstract] [Full Text] [Related]
19. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
Ndashimye E; Arts EJ
Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
